Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy represents the most common monogenic cause of hereditary small vessel disease. Pathologists identify vascular NOTCH3 aggregation as the central hallmark of this disabling neurovascular disorder. Although cysteine-altering mutations in NOTCH3 drive this arteriopathy, clinical manifestations range from early disabling strokes to mild late-onset presentations. Consequently, clinicians have long sought reliable biomarkers to predict individual patient trajectory. Recent multicenter cohort evidence demonstrates that quantified vascular aggregation in peripheral vessels directly mirrors neurovascular compromise and disease severity.

The Pathological Role of NOTCH3 Aggregation in CADASIL

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, known as CADASIL, leads to recurrent subcortical ischemic events and vascular dementia. Typically, pathogenic variants alter the number of cysteine residues within the 34 epidermal growth factor-like repeat domains of the receptor. Consequently, this biochemical defect causes abnormal multimerization and extensive NOTCH3 aggregation within vascular smooth muscle cells. Electron microscopy demonstrates these abnormal protein accumulations as granular osmiophilic material within systemic arteriolar walls. Furthermore, progressive extracellular accumulation damages vascular smooth muscle architecture, thereby compromising cerebral microvascular autoregulation. Over time, vessel wall thickening causes progressive lumen stenosis and obliterative arteriopathy in penetrating cerebral arteries. In addition, chronic hypoperfusion triggers diffuse white matter demyelination, lacunar infarctions, and microbleeds throughout deep cerebral structures. Importantly, clinical severity varies widely even among individuals harboring identical genetic variants. For instance, some individuals experience catastrophic ischemic strokes in their early forties, whereas others remain relatively asymptomatic well into late adulthood. Therefore, understanding whether the physical extent of microvascular protein deposition reflects biological aggressiveness has emerged as a fundamental neurovascular inquiry.

Skin Biopsy Analysis and the NOTCH3 Score Methodology

Evaluating small vessel pathology in living patients has traditionally posed substantial challenges because cerebral arterioles remain inaccessible without invasive brain surgery. However, systemic microvessels replicate the characteristic arteriopathy observed in cerebral tissue. Therefore, clinicians frequently obtain punch skin biopsies from the upper arm or leg to assess granular osmiophilic material deposits. In a prospective cohort study of 212 patients, investigators calculated an objective immunohistochemical metric termed the NOTCH3 score. Specifically, researchers measured the exact fraction of the skin vessel wall area displaying positive immunostaining for the NOTCH3 extracellular domain. Pathologists analyzed 39 distinct cysteine-altering NOTCH3 variants across the study population to evaluate deposition patterns. Furthermore, the authors computed variant-specific NOTCH3 scores for mutations present in ten or more cohort participants. By averaging scores among individuals who share specific mutations, the team generated reproducible measures of protein accumulation propensity. Notably, the quantified vessel wall involvement remained stable across adult age brackets, indicating that aggregation propensity serves as a static marker rather than a purely time-dependent wear phenomenon. Thus, skin biopsy provides an accessible diagnostic window into systemic microvascular burden.

Correlation with Neuroimaging Markers and Lifetime Stroke Risk

The clinical utility of any tissue biomarker depends strictly upon its ability to predict objective organ injury. In this prospective investigation, researchers examined how skin vessel scores associate with validated neuroimaging markers and clinical events. Consequently, multivariable linear mixed models and Cox regression revealed compelling relationships between vascular accumulation and cerebral damage. Specifically, higher scores strongly correlated with increased white matter hyperintensity volume on brain magnetic resonance imaging. Furthermore, elevated vessel wall staining predicted extensive lacunar infarction load, larger microbleed counts, and higher mean skeletonized diffusivity across cerebral white matter tracts. These neuroimaging features represent reliable radiological hallmarks of progressing small vessel arteriopathy and impending cognitive deterioration. Beyond structural neuroimaging, the NOTCH3 score significantly associated with overall lifetime stroke probability. Mediation analyses demonstrated that vascular protein burden directly mediates a substantial proportion of the cerebrovascular damage historically attributed to pathogenic variants. Importantly, these statistical models controlled for common vascular risk factors including arterial hypertension, dyslipidemia, and smoking status. Accordingly, the findings confirm that microvascular protein accumulation directly dictates downstream neurological events.

Genotype Variations and Domain-Specific Severity Discrepancies

Previous genetic studies identified a notable divergence in CADASIL phenotypes based on mutation position. Specifically, cysteine-altering variants situated within epidermal growth factor-like repeat domains 1 through 6 confer a significantly higher risk of early stroke compared with variants in domains 7 through 34. However, the exact biophysical reason for this phenotypic gradient remained unexplained for years. The prospective cohort data now provide an elegant biological explanation for these differences. Notably, variant-specific NOTCH3 scores accurately reflect the divergence in clinical severity observed across distinct mutations. Patients with high-risk proximal variants exhibit substantially denser vascular protein deposition in systemic microvessels. Conversely, patients carrying distal variants demonstrate significantly lower staining fractions and markedly slower neurovascular degeneration. Furthermore, these results help clarify why certain distal variants display reduced penetrance in general population biobanks. Because distinct mutations exhibit differing intrinsic propensities to misfold and aggregate, microvascular wall disruption occurs at variable rates. Therefore, incorporating variant-specific accumulation profiles allows neurologists to transcend generic prognostic labels. Ultimately, assessing aggregation propensity illuminates the distinct biological behavior characterizing diverse mutations throughout the extracellular receptor structure.

Clinical Translation for Risk Stratification and Genetic Counseling

Integrating variant-specific aggregation profiles into clinical workflow will significantly refine patient counseling and therapeutic monitoring. Currently, receiving a genetic diagnosis of CADASIL causes immense psychological distress because existing guidelines offer limited personalized prognostic information. However, clinicians can now provide more nuanced predictive guidance based on variant-specific aggregation propensity and standardized risk tiers. Additionally, this biomarker framework supports rigorous design for future neuroprotective clinical trials. For example, selecting participants based purely on genetic status introduces significant heterogeneity because disease trajectories vary substantially. By stratifying clinical trial participants according to NOTCH3 aggregation load and mutation severity groups, investigators can accurately measure treatment effects on microvascular stabilization. Furthermore, aggressive vascular risk factor management remains paramount for all patients, particularly those with high aggregation scores. Clinicians must strictly control systolic blood pressure, manage metabolic parameters, and support smoking cessation to avoid compounding intrinsic arteriopathy with acquired atherosclerosis. In addition, multidisciplinary neurovascular teams must coordinate longitudinal brain magnetic resonance imaging to monitor asymptomatic disease progression. Thus, variant-specific metrics bridge basic molecular genetics and individualized patient care.

Frequently Asked Questions

How does NOTCH3 aggregation contribute to small vessel pathology?

Mutations altering cysteine residues in the extracellular domain prompt NOTCH3 aggregation along vascular smooth muscle cells. Consequently, these protein deposits form granular osmiophilic material within small arterioles. This progressive accumulation disrupts smooth muscle integrity, thickens vessel walls, impairs cerebral blood flow autoregulation, and ultimately triggers ischemic lacunar infarcts and white matter damage.

Why is skin biopsy useful for evaluating CADASIL progression?

Because CADASIL represents a generalized systemic arteriopathy, cutaneous arterioles exhibit identical extracellular protein accumulation as deep cerebral vessels. Therefore, punch skin biopsy provides an accessible, minimally invasive surrogate tissue. By quantifying the NOTCH3 score in skin microvasculature, pathologists can accurately evaluate systemic microvascular deposition load without requiring invasive brain biopsies.

How do epidermal growth factor-like repeat positions influence prognosis?

Variants located in epidermal growth factor-like repeats 1 through 6 exhibit much higher aggregation propensity, leading to earlier stroke onset and accelerated cognitive decline. Conversely, variants located in repeats 7 through 34 generally show lower aggregation loads, milder radiological small vessel disease, delayed clinical symptoms, and occasionally incomplete clinical penetrance.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Cerfontaine MN et al. Association Between Vascular NOTCH3 Aggregation and Disease Severity in a CADASIL Cohort - Implications for NOTCH3 Variant-Specific Disease Prediction. Ann Neurol. 2025 Aug. doi: 10.1002/ana.27240. PMID: 40265482.
2. Rutten JW, Hack RJ, Duering M, et al. The effect of NOTCH3 pathogenic variant position on CADASIL disease severity. Genet Med. 2019;21(3):676-682.
3. Hack RJ, Gravesteijn G, Cerfontaine MN, et al. Association of NOTCH3 Variant Risk Category With 2-Year Clinical and Radiologic Small Vessel Disease Progression in Patients With CADASIL. Neurology. 2024;102(11):e209487.
4. Cerfontaine MN, Hack RJ, Terwindt GM, et al. Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL. JAMA Neurol. 2025;82(2):161-170.